Recently, the globally renowned growth consulting firm Frost & Sullivan released the 'China Innovative Biopharmaceutical Market Research Report'. The report provides a detailed analysis of the market demand and competition for innovative biopharmaceuticals globally and in China, including PD-1 monoclonal antibodies, anti-CD20 monoclonal antibodies, COVID-19 neutralizing antibodies, etc.
I. Overview of the Pharmaceutical Industry(example)
1. Global overview of the pharmaceutical industry
Under the combined influence of aging populations, social healthcare expenditures, and R&D investment, the global pharmaceutical market has maintained stable growth in the past. The global pharmaceutical market size increased from $1 trillion in 2014 to $1.3 trillion in 2019. It is expected that the global pharmaceutical market size will reach $1.6 trillion (16,395) by 2024 and further climb to $2.1 trillion by 2030. The global pharmaceutical market is essentially composed of two major sectors: chemical drugs and biopharmaceuticals.
2015 - 2030Global Pharmaceutical Market Size (Expected)
…
2. General Overview of the Development of China's Pharmaceutical Industry
Affected by both the decline in birth rates and the increase in life expectancy, China's aging population is growing at a rate much faster than the global average. From 2015 to 2019, the population aged 65 and above in China increased from 140 million to 170 million, accounting for 12.6% of the total population. From 2015 to 2019, China's total healthcare expenditure increased from 4.1 trillion yuan to 6.5 trillion yuan. China's investment in pharmaceutical research and development also grew rapidly from $10.5 billion in 2015 to $21.1 billion in 2019.
……
3. Tumor market situation
(1) Global and Chinese Oncology Overview
Cancer treatment has undergone a development process from surgical resection to the concurrent use of radiotherapy, chemotherapy, targeted therapy, immunotherapy, and other modalities.
……
(2) Global and Chinese Oncology Epidemiology Analysis
Driven by various factors, the global annual number of new cancer cases increased from 16.8 million in 2015 to 18.5 million in 2019.
……
II. Market segmentation of innovative biopharmaceuticals
1. Hemophilia drug market situation
1.1 Global
1.1.1 International market demand
The global number of hemophilia patients increased from 742,000 in 2015 to 783,000 in 2019, with a compound growth rate of 1.3%.
……
1.1.2 International Competitive Landscape
1.2 China
1.2.1 Chinese market demand
1.2.2 China market size
1.2.3 Competitive landscape
2. Market segmentation of tumors
2.1 PD-1monoclonal antibody
2.1.1 Market demand
1) Liver cancer
2) Esophageal cancer
3) Gastric cancer
4) Lung cancer
5) Nasopharyngeal carcinoma
2.1.2 Market Scale
The Chinese PD-1 and PD-L1 inhibitor market reached 6.3 billion in 2019 and is expected to grow at a compound annual growth rate of 67.0% to reach 819 billion yuan by 2024, followed by a compound annual growth rate of 3.4% to reach 1000 billion yuan by 2030.
Data source: Annual reports of listed companies, analysis by Frost & Sullivan
2.1.3 Competitive landscape
2.2resistCD20monoclonal antibody
2.3 VEGFMonoclonal antibody, bevacizumab biosimilar
2.4 EGFRmonoclonal antibody
3. HPVVaccine market situation
3.1 Market demand
HPV infection is associated with a variety of cancers and diseases, especially cervical cancer. Cervical cancer is the fourth most common cancer among women globally. The World Health Organization has identified a total of 12 high-risk carcinogenic HPV virus types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59). In 2019, the number of cervical cancer cases in China was 117,000, and it is expected to increase to 123,000 by 2024 at a compound annual growth rate of 0.9%, and then to 126,000 by 2030 at a compound annual growth rate of 0.4%.
……
3.2 Market Scale
Since the approval and issuance of the bivalent HPV vaccine in China for the first time in 2017, quadrivalent and nonavalent vaccines have also been introduced into the market in 2017 and 2018 respectively. In 2020, the domestically produced bivalent HPV vaccine Xinkening was launched. According to data from the National Institutes for Food and Drug Control, a total of 1.455 million doses of HPV vaccines were sold in the Chinese market in 2017, 7.128 million doses in 2018, and 10.417 million and 15.432 million doses in 2019 and 2020 respectively, with year-on-year growth rates of 389.9%, 46.1%, and 48.1%, indicating the huge clinical demand and market potential for HPV vaccines in China.
Source: China Inspection and Quarantine Institute, analysis by Frost & Sullivan
3.3 Competitive Landscape
4. Market situation of wet age-related macular degenerationVEGFMonoclonal antibodies and their biosimilars)
5. Market situation of COVID-19 neutralizing antibodies
5.1 International market demand
Coronaviruses are a large class of viruses that can cause diseases in animals or humans. They are widely distributed across many different species, including bats, cattle, cats, birds, and camels, and are also one of the pathogens causing respiratory infections in humans. Coronaviruses are RNA viruses, and several known coronaviruses can cause respiratory infections, ranging from the common cold to severe diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The mortality rate of the SARS-CoV coronavirus is 10%, while that of the MERS-CoV coronavirus is 34.4%.
The 2019 novel coronavirus (SARS-CoV-2, which causes COVID-19) is currently the seventh known coronavirus capable of infecting humans. The susceptible population mainly includes the elderly, children, and pregnant women. Common symptoms after infection with the coronavirus include respiratory symptoms, fever, cough, shortness of breath, and difficulty breathing. In more severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death. The main transmission routes of COVID-19 include droplet transmission, aerosol transmission, contact transmission, and mother-to-child transmission. Currently, there are no specific treatments for diseases caused by the novel coronavirus; the focus is on symptomatic treatment and supportive care.
As of February 25, 2021, there have been a total of 112,209,815 COVID-19 cases globally, resulting in 2,490,776 deaths. The global incidence rate is still on the rise.
Source: WHO, analysis by Frost & Sullivan
……
5.2 International Market Size
5.3 Competitive Landscape
6. Market situation of drugs for autoimmune diseases
The above isResearch Report on the Chinese Innovative Biopharmaceutical MarketFor an overview of some of the content, or to read or purchase the full report, please contact Frost & Sullivan.
